Cantor Fitzgerald Brokers Lift Earnings Estimates for BMRN

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Cantor Fitzgerald boosted their FY2025 earnings per share (EPS) estimates for BioMarin Pharmaceutical in a report issued on Thursday, February 20th. Cantor Fitzgerald analyst O. Brayer now expects that the biotechnology company will post earnings per share of $3.53 for the year, up from their prior estimate of $3.09. Cantor Fitzgerald has a “Overweight” rating and a $90.00 price target on the stock. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $3.15 per share.

Several other analysts have also commented on BMRN. Piper Sandler lifted their price target on shares of BioMarin Pharmaceutical from $122.00 to $126.00 and gave the company an “overweight” rating in a research report on Thursday, February 20th. JPMorgan Chase & Co. reduced their price objective on shares of BioMarin Pharmaceutical from $110.00 to $109.00 and set an “overweight” rating on the stock in a report on Wednesday, October 30th. UBS Group increased their target price on shares of BioMarin Pharmaceutical from $109.00 to $113.00 and gave the stock a “buy” rating in a research note on Thursday, February 20th. Oppenheimer raised shares of BioMarin Pharmaceutical from a “market perform” rating to an “outperform” rating and set a $98.00 price target on the stock in a research note on Monday. Finally, Canaccord Genuity Group lowered their price objective on shares of BioMarin Pharmaceutical from $93.00 to $84.00 and set a “hold” rating for the company in a research report on Wednesday, October 30th. Seven equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $94.00.

BioMarin Pharmaceutical Price Performance

Shares of BMRN stock opened at $69.00 on Monday. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.33 and a quick ratio of 2.62. The company has a market capitalization of $13.15 billion, a PE ratio of 31.36, a price-to-earnings-growth ratio of 0.61 and a beta of 0.28. The firm’s 50-day moving average is $64.95 and its two-hundred day moving average is $70.61. BioMarin Pharmaceutical has a 12 month low of $60.63 and a 12 month high of $94.85.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 EPS for the quarter, topping the consensus estimate of $0.54 by $0.18. The business had revenue of $747.31 million for the quarter, compared to analyst estimates of $711.05 million. BioMarin Pharmaceutical had a return on equity of 9.91% and a net margin of 14.96%.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. LRI Investments LLC raised its holdings in shares of BioMarin Pharmaceutical by 856.9% in the 4th quarter. LRI Investments LLC now owns 488 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 437 shares in the last quarter. TD Private Client Wealth LLC increased its holdings in BioMarin Pharmaceutical by 57.4% in the third quarter. TD Private Client Wealth LLC now owns 510 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 186 shares during the last quarter. SBI Securities Co. Ltd. acquired a new stake in BioMarin Pharmaceutical in the fourth quarter valued at $36,000. CIBC Private Wealth Group LLC lifted its holdings in BioMarin Pharmaceutical by 64.2% during the 4th quarter. CIBC Private Wealth Group LLC now owns 596 shares of the biotechnology company’s stock worth $41,000 after buying an additional 233 shares during the last quarter. Finally, Meeder Asset Management Inc. boosted its position in shares of BioMarin Pharmaceutical by 920.8% during the 3rd quarter. Meeder Asset Management Inc. now owns 735 shares of the biotechnology company’s stock worth $52,000 after acquiring an additional 663 shares in the last quarter. Hedge funds and other institutional investors own 98.71% of the company’s stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.